Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 31, 2020, titled "Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mgand Apremilast Tablets, 10 mg, 20 mg and 30 mg".